anti-TNF-alpha (mouse), mAb (blocking) (V1q) (preservative free)
| Code | Size | Price |
|---|
| AG-20B-0081PF-C100 | 100 ug | £280.00 |
Quantity:
| AG-20B-0081PF-C500 | 500 ug | £820.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
Blue Ice
Storage:
-20°C
Further Information
Alternate Names/Synonyms:
Tumor Necrosis Factor Ligand Superfamily Member 2; TNFSF2; Cachectin
Concentration:
1mg/ml
EClass:
32160000
Endotoxin:
<0.01EU/µg purified protein (LAL test).
Form (Short):
liquid
Formulation:
Liquid. In PBS.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Cytotoxin purified from ConA induced T cell clone 29.
Labels - Conjugates:
Preservative Free
Long Description:
Monoclonal Antibody. Recognizes mouse TNF-alpha. Reacts with both natural and recombinant mouse TNF-alpha. It does not cross-react with human TNF-alpha and TNF-beta (Lymphotoxin-alpha). Application: FACS, FUNC. Clone: V1q. Isotype: Rat IgG. Liquid. In PBS. Tumor necrosis factor (TNF, cachexin or cachectin and formerly known as tumor necrosis factor-α) is a cytokine involved in systemic inflammation and metabolism and is a member of a group of cytokines that stimulate the acute phase reaction. It causes tumor necrosis in vivo and shows also cytolytic activity against tumors. Signal transduction occurs via two types of TNF-receptors, the TNF-receptors 1 and 2. The receptor TNF-R1 is activated by both the membrane-bound and soluble trimeric forms of TNF-α, whereas the receptor TNF-R2 only responds to the membrane-bound form of TNF-α. The monoclonal antibody V1q recognizes endogenous mouse Tumor Necrosis Factor-α.
Package Type:
Plastic Vial
Product Description:
Tumor necrosis factor (TNF, cachexin or cachectin and formerly known as tumor necrosis factor-alpha) is a cytokine involved in systemic inflammation and metabolism and is a member of a group of cytokines that stimulate the acute phase reaction. It causes tumor necrosis in vivo and shows also cytolytic activity against tumors. Signal transduction occurs via two types of TNF-receptors, the TNF-receptors 1 and 2. The receptor TNF-R1 is activated by both the membrane-bound and soluble trimeric forms of TNF-alpha, whereas the receptor TNF-R2 only responds to the membrane-bound form of TNF-alpha. The monoclonal antibody V1q recognizes endogenous mouse TNF-alpha.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes mouse TNF-alpha. Reacts with both natural and recombinant mouse TNF-alpha. It does not cross-react with human TNF-alpha and TNF-beta (Lymphotoxin-alpha).
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis: B. Echtenacher, et al.; J. Immunol. 145, 3762 (1990) | Pharmacologic Inhibitors of Tumor Necrosis Factor Production Exert Differential Effects in Lethal Endotoxemia and in Infection with Live Microorganisms in Mice: M.G. etea, et al.; J. Inf. Dis. 171, 393 (1995) | A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome: M.J. Jansen, et al.; Cytokine 10, 904 (1998) | Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis: H. Schadlich, et al.; Ann. Rheum. Dis. 58, 428 (1999) | Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke: A. Martin-Villablba, et al.; Cell Death Diff. 8, 679 (2001) | Roles of tumor necrosis factor p55 and p75 receptors in TNF-a-induced vascular permeability: E. Ferrero, et al.; Am. J. Physiol. Cell Physiol. 281, C1173 (2001) | Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration: F. Curnis, et al.; J. Clin. Invest. 110, 475 (2002) | An Anti-Tumor Necrosis Factor-alpha Antibody Inhibits the Development of Experimental Skin Tumors: K.A. Scott, et al.; Mol. Cancer Therap. 2, 445 (2003) | Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury: D. Demjen, et al.; Nat. Med. 10, 389 (2004) | Blockade of TNF-alpha Decreases Both Inflammation and Efficacy of Intrapulmonary Ad.IFNbeta Immunotherapy in an Orthotopic Model of Bronchogenic Lung Cancer: M.J. Wilderman, et al.; Mol. Ther. 13, 910 (2006) | Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha: I. Goren, et al.; Am. J. Pathol. 168, 765 (2006) | Systemic Anti-TNFalpha Treatment Restores Diabetes-Impaired Skin Repair in ob/ob Mice by Inactivation of Macrophages: I. Goren, et al.; J. Clin. Invest. 127, 2259 (2007) | Tumor Necrosis Factor a Sensitizes Primary Murine Hepatocytes to Fas/CD95-Induced Apoptosis in a Bim- and Bid-Dependent Manner: K. Schmich, et al.; Hepatol. 53, 282 (2011) | TNF signaling drives myeloid-derived suppressor cell accumulation: X. Zhao, et al.; J. Clin. Invest. 122, 4094 (2012) | Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments: F. Depis, et al.; Arthr. Rheumatol. 64, 3189 (2012) | Targeting Endothelial CD146 Attenuates Colitis and Prevents Colitis-Associated Carcinogenesis: S. Xing, et al.; Am. J. Pathol. 184, 1604 (2014)